Cargando…

Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors

BACKGROUND: Renal dysfunction after acute kidney injury (AKI) is common, potentially modifiable, but poorly understood. Acute kidney disease (AKD) describes renal dysfunction 7 to 90 days after AKI and is determined by percentage change in creatinine from baseline. Chronic kidney disease (CKD) is de...

Descripción completa

Detalles Bibliográficos
Autores principales: Rimes-Stigare, Claire, Ravn, Bo, Awad, Akil, Torlén, Klara, Martling, Claes-Roland, Bottai, Matteo, Mårtensson, Johan, Bell, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180984/
https://www.ncbi.nlm.nih.gov/pubmed/30363702
http://dx.doi.org/10.1155/2018/7698090
_version_ 1783362325837774848
author Rimes-Stigare, Claire
Ravn, Bo
Awad, Akil
Torlén, Klara
Martling, Claes-Roland
Bottai, Matteo
Mårtensson, Johan
Bell, Max
author_facet Rimes-Stigare, Claire
Ravn, Bo
Awad, Akil
Torlén, Klara
Martling, Claes-Roland
Bottai, Matteo
Mårtensson, Johan
Bell, Max
author_sort Rimes-Stigare, Claire
collection PubMed
description BACKGROUND: Renal dysfunction after acute kidney injury (AKI) is common, potentially modifiable, but poorly understood. Acute kidney disease (AKD) describes renal dysfunction 7 to 90 days after AKI and is determined by percentage change in creatinine from baseline. Chronic kidney disease (CKD) is defined as the estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m(2) persisting for more than 90 days(.) We compared CKD incidence using both creatinine- and cystatin C-based GFR with AKD incidence at 90 days in AKI survivors. METHODS: A prospective cohort study was conducted in a Swedish intensive care unit (ICU) between 2008 and 2010. We included AKI patients alive at 90 days. We excluded patients <18 and >100 years, death before follow-up, CKD prior to admission, and follow-up before 60 days or beyond 270 days. Creatinine and cystatin C were measured at 90 days and converted to eGFR (mL/min/1.73 m(2)). RESULTS: We included 274 patients. At 90-day follow-up, the median creatinine eGFR (MDRD) was 81.6 (IQR 58.6–106.8) and median cystatin C eGFR was 51.5 (IQR 35.8–70.7). The incidence of CKD (eGFR < 60) was 25.8% based on creatinine but 63.7% using cystatin C estimates. AKD was present in 47 patients (18.9%). Age, discharge cystatin C, creatinine at discharge, and female gender predicted creatinine-defined CKD at follow-up. Age, discharge cystatin C, CRRT on ICU, and diabetes were associated with cystatin C-based CKD. CONCLUSIONS: In AKI survivors followed up at 3 months, CKD criteria were met in a quarter of patients using creatinine and in two-thirds using cystatin C eGFR. Less than one-fifth of patients fulfilled AKD criteria. The application of AKD criteria may underestimate renal dysfunction in AKI survivors.
format Online
Article
Text
id pubmed-6180984
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61809842018-10-24 Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors Rimes-Stigare, Claire Ravn, Bo Awad, Akil Torlén, Klara Martling, Claes-Roland Bottai, Matteo Mårtensson, Johan Bell, Max Crit Care Res Pract Research Article BACKGROUND: Renal dysfunction after acute kidney injury (AKI) is common, potentially modifiable, but poorly understood. Acute kidney disease (AKD) describes renal dysfunction 7 to 90 days after AKI and is determined by percentage change in creatinine from baseline. Chronic kidney disease (CKD) is defined as the estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m(2) persisting for more than 90 days(.) We compared CKD incidence using both creatinine- and cystatin C-based GFR with AKD incidence at 90 days in AKI survivors. METHODS: A prospective cohort study was conducted in a Swedish intensive care unit (ICU) between 2008 and 2010. We included AKI patients alive at 90 days. We excluded patients <18 and >100 years, death before follow-up, CKD prior to admission, and follow-up before 60 days or beyond 270 days. Creatinine and cystatin C were measured at 90 days and converted to eGFR (mL/min/1.73 m(2)). RESULTS: We included 274 patients. At 90-day follow-up, the median creatinine eGFR (MDRD) was 81.6 (IQR 58.6–106.8) and median cystatin C eGFR was 51.5 (IQR 35.8–70.7). The incidence of CKD (eGFR < 60) was 25.8% based on creatinine but 63.7% using cystatin C estimates. AKD was present in 47 patients (18.9%). Age, discharge cystatin C, creatinine at discharge, and female gender predicted creatinine-defined CKD at follow-up. Age, discharge cystatin C, CRRT on ICU, and diabetes were associated with cystatin C-based CKD. CONCLUSIONS: In AKI survivors followed up at 3 months, CKD criteria were met in a quarter of patients using creatinine and in two-thirds using cystatin C eGFR. Less than one-fifth of patients fulfilled AKD criteria. The application of AKD criteria may underestimate renal dysfunction in AKI survivors. Hindawi 2018-09-27 /pmc/articles/PMC6180984/ /pubmed/30363702 http://dx.doi.org/10.1155/2018/7698090 Text en Copyright © 2018 Claire Rimes-Stigare et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rimes-Stigare, Claire
Ravn, Bo
Awad, Akil
Torlén, Klara
Martling, Claes-Roland
Bottai, Matteo
Mårtensson, Johan
Bell, Max
Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
title Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
title_full Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
title_fullStr Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
title_full_unstemmed Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
title_short Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
title_sort creatinine- and cystatin c-based incidence of chronic kidney disease and acute kidney disease in aki survivors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180984/
https://www.ncbi.nlm.nih.gov/pubmed/30363702
http://dx.doi.org/10.1155/2018/7698090
work_keys_str_mv AT rimesstigareclaire creatinineandcystatincbasedincidenceofchronickidneydiseaseandacutekidneydiseaseinakisurvivors
AT ravnbo creatinineandcystatincbasedincidenceofchronickidneydiseaseandacutekidneydiseaseinakisurvivors
AT awadakil creatinineandcystatincbasedincidenceofchronickidneydiseaseandacutekidneydiseaseinakisurvivors
AT torlenklara creatinineandcystatincbasedincidenceofchronickidneydiseaseandacutekidneydiseaseinakisurvivors
AT martlingclaesroland creatinineandcystatincbasedincidenceofchronickidneydiseaseandacutekidneydiseaseinakisurvivors
AT bottaimatteo creatinineandcystatincbasedincidenceofchronickidneydiseaseandacutekidneydiseaseinakisurvivors
AT martenssonjohan creatinineandcystatincbasedincidenceofchronickidneydiseaseandacutekidneydiseaseinakisurvivors
AT bellmax creatinineandcystatincbasedincidenceofchronickidneydiseaseandacutekidneydiseaseinakisurvivors